US FDA guidance explains how to display proprietary and established drug names in promotional material
This article was originally published in SRA
The US Food and Drug Administration has issued final guidance for prescription drug manufacturers clarifying how they may display the proprietary and established names of drug products in promotional materials, including advertisements disseminated via social media websites1,2.
You may also be interested in...
Five new drugs have been recommended for EU approval at the latest meeting of European Medicines Agency’s drug evaluation committee.
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.